{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022310","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.562929+00:00","generated_at":"2026-05-16T20:30:51.541207+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Anebulo Pharma Q1 net loss $2.2M; advances IV selonabant Phase 1 study","bullets":["Net loss of $2.2M ($0.05/sh) in Q1 FY2026, flat vs prior year; operating expenses $2.3M.","Cash $10.4M at Sept 30, 2025; plus $3M available under loan agreement.","First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric cannabis toxicity; FDA-cleared design.","Received $994,300 second-year tranche of NIDA/NIH grant to support the SAD study.","Board continues strategic review including proposed reverse stock split and going-private transaction; SEC comments delayed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022310","json":"https://secwatch.observer/filing/0001493152-25-022310.json","markdown":"https://secwatch.observer/filing/0001493152-25-022310.md","text":"https://secwatch.observer/filing/0001493152-25-022310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/0001493152-25-022310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315225022310/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:30:51.541207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}